---
document_datetime: 2025-12-02 05:14:04
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zilbrysq.html
document_name: zilbrysq.html
version: success
processing_time: 0.1043152
conversion_datetime: 2025-12-27 17:50:55.648175
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zilbrysq

[RSS](/en/individual-human-medicine.xml/77402)

##### Authorised

This medicine is authorised for use in the European Union

zilucoplan Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Zilbrysq](#news-on)
- [More information on Zilbrysq](#more-information-on-zilbrysq-64265)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Zilbrysq is a medicine used to treat generalised myasthenia gravis (a disease that leads to muscle weakness and tiredness) in adults whose immune system produces antibodies against a protein called the acetylcholine receptor. It is given together with other medicines used for treating myasthenia gravis.

Zilbrysq contains the active substance zilucoplan.

Expand section

Collapse section

## How is Zilbrysq used?

The medicine can only be obtained with a prescription. Treatment with Zilbrysq should be supervised by healthcare professionals experienced in managing patients with neuromuscular disorders (disorders that affect the nerves that control muscles).

Zilbrysq is given as an injection under the skin once daily. The dose depends on the patient's body weight. The patient or their carer can give the injection if they have been trained appropriately.

For more information about using Zilbrysq, see the package leaflet or contact your doctor or pharmacist.

## How does Zilbrysq work?

The active substance in Zilbrysq, zilucoplan, is designed to attach to the C5 complement protein, which is part of the immune system called the 'complement system'.

Myasthenia gravis is caused by the production of autoantibodies (proteins that attack parts of a person's own body by mistake) that damage acetylcholine receptors, which in normal conditions allow signals from the nerves to trigger muscle contractions. The attachment of autoantibodies to acetylcholine receptors activates the complement system, which leads to damage of the contact point between the nerve and muscle. Due to this damage, the muscles are not able to contract as well as normal, leading to muscle weakness and difficulty moving. By attaching to the C5 complement protein, zilucoplan reduces the activity of the complement system, which decreases the damage of acetylcholine receptors thereby improving the symptoms of the disease.

## What benefits of Zilbrysq have been shown in studies?

A study involving 174 adults with generalised myasthenia gravis and anti-acetylcholine receptor autoantibodies showed that Zilbrysq was more effective than placebo (a dummy treatment) at improving symptoms of the disease.

The effect of treatment was measured using the Myasthenia Gravis - Activities of Daily Living (MG-ADL) scale, a scoring system for assessing the impact of the disease on a patient's daily life. A reduction in a patient's MG-ADL score means that there has been an improvement in their disease symptoms.

The study showed that after 12 weeks of treatment, patients given Zilbrysq had a reduction of about 4.4 points in the MG-ADL score compared to a reduction of 2.3 points in those given placebo.

## What are the risks associated with Zilbrysq?

For the full list of side effects and restrictions with Zilbrysq, see the package leaflet.

The most common side effects with Zilbrysq (which may affect more than 1 in 10 people) include injection site reactions, such as bruising and pain, and upper respiratory tract (nose and throat) infections.

Due to an increased risk of developing meningococcal infection caused by the bacterium Neisseria meningitidis, Zilbrysq must not be given to patients who have an ongoing meningococcal infection. It should not be used in patients who have not been vaccinated against this bacterium at least two weeks before starting treatment. If treatment is started within two weeks of vaccination, patients should take appropriate antibiotics for two weeks after vaccination.

## Why is Zilbrysq authorised in the EU?

Zilbrysq was shown to improve the symptoms of generalised myasthenia gravis in patients with anti-acetylcholine receptor autoantibodies. Given that patients can inject the medicine themselves, it provides an accessible treatment option for the disease. Although side effects with Zilbrysq were generally mild to moderate, there are some uncertainties about the medicine's long-term safety, given that the studies included a small number of patients for a relatively short period of time.

The European Medicines Agency therefore decided that Zilbrysq's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Zilbrysq?

The company that markets Zilbrysq will ensure that patients can only access the medicine if their prescribers have made a written declaration of their vaccination against meningococcal disease. The company will also send reminders to prescribers to check if re-vaccination is needed for patients taking Zilbrysq and provide healthcare professionals and patients with safety information on the risk of meningococcal infections with the medicine. Patients will also be given an alert card that explains the symptoms of meningococcal infection and when to seek immediate medical care.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zilbrysq have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Zilbrysq are continuously monitored. Suspected side effects reported with Zilbrysq are carefully evaluated and any necessary action taken to protect patients.

## Other information about Zilbrysq

Zilbrysq received a marketing authorisation valid throughout the EU on 1 December 2023.

Zilbrysq : EPAR - Medicine overview

Reference Number: EMA/509663/2023

English (EN) (122.64 KB - PDF)

**First published:** 08/12/2023

[View](/en/documents/overview/zilbrysq-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-772)

български (BG) (139.02 KB - PDF)

**First published:**

08/12/2023

[View](/bg/documents/overview/zilbrysq-epar-medicine-overview_bg.pdf)

español (ES) (114.09 KB - PDF)

**First published:**

08/12/2023

[View](/es/documents/overview/zilbrysq-epar-medicine-overview_es.pdf)

čeština (CS) (136.42 KB - PDF)

**First published:**

08/12/2023

[View](/cs/documents/overview/zilbrysq-epar-medicine-overview_cs.pdf)

dansk (DA) (113.17 KB - PDF)

**First published:**

08/12/2023

[View](/da/documents/overview/zilbrysq-epar-medicine-overview_da.pdf)

Deutsch (DE) (116.68 KB - PDF)

**First published:**

08/12/2023

[View](/de/documents/overview/zilbrysq-epar-medicine-overview_de.pdf)

eesti keel (ET) (113.36 KB - PDF)

**First published:**

08/12/2023

[View](/et/documents/overview/zilbrysq-epar-medicine-overview_et.pdf)

ελληνικά (EL) (145.27 KB - PDF)

**First published:**

08/12/2023

[View](/el/documents/overview/zilbrysq-epar-medicine-overview_el.pdf)

français (FR) (116.6 KB - PDF)

**First published:**

08/12/2023

[View](/fr/documents/overview/zilbrysq-epar-medicine-overview_fr.pdf)

hrvatski (HR) (135.52 KB - PDF)

**First published:**

08/12/2023

[View](/hr/documents/overview/zilbrysq-epar-medicine-overview_hr.pdf)

italiano (IT) (112.63 KB - PDF)

**First published:**

08/12/2023

[View](/it/documents/overview/zilbrysq-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (142.5 KB - PDF)

**First published:**

08/12/2023

[View](/lv/documents/overview/zilbrysq-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (137.45 KB - PDF)

**First published:**

08/12/2023

[View](/lt/documents/overview/zilbrysq-epar-medicine-overview_lt.pdf)

magyar (HU) (135.71 KB - PDF)

**First published:**

08/12/2023

[View](/hu/documents/overview/zilbrysq-epar-medicine-overview_hu.pdf)

Malti (MT) (138.11 KB - PDF)

**First published:**

08/12/2023

[View](/mt/documents/overview/zilbrysq-epar-medicine-overview_mt.pdf)

Nederlands (NL) (113.56 KB - PDF)

**First published:**

08/12/2023

[View](/nl/documents/overview/zilbrysq-epar-medicine-overview_nl.pdf)

polski (PL) (138.6 KB - PDF)

**First published:**

08/12/2023

[View](/pl/documents/overview/zilbrysq-epar-medicine-overview_pl.pdf)

português (PT) (114.66 KB - PDF)

**First published:**

08/12/2023

[View](/pt/documents/overview/zilbrysq-epar-medicine-overview_pt.pdf)

română (RO) (134.29 KB - PDF)

**First published:**

08/12/2023

[View](/ro/documents/overview/zilbrysq-epar-medicine-overview_ro.pdf)

slovenčina (SK) (135.05 KB - PDF)

**First published:**

08/12/2023

[View](/sk/documents/overview/zilbrysq-epar-medicine-overview_sk.pdf)

slovenščina (SL) (133.67 KB - PDF)

**First published:**

08/12/2023

[View](/sl/documents/overview/zilbrysq-epar-medicine-overview_sl.pdf)

Suomi (FI) (111.51 KB - PDF)

**First published:**

08/12/2023

[View](/fi/documents/overview/zilbrysq-epar-medicine-overview_fi.pdf)

svenska (SV) (112.77 KB - PDF)

**First published:**

08/12/2023

[View](/sv/documents/overview/zilbrysq-epar-medicine-overview_sv.pdf)

Zilbrysq : EPAR - Risk management plan

English (EN) (4.42 MB - PDF)

**First published:** 08/12/2023

[View](/en/documents/rmp/zilbrysq-epar-risk-management-plan_en.pdf)

## Product information

Zilbrysq : EPAR - Product information

English (EN) (976.51 KB - PDF)

**First published:** 08/12/2023

**Last updated:** 26/11/2025

[View](/en/documents/product-information/zilbrysq-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-460)

български (BG) (735.91 KB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/bg/documents/product-information/zilbrysq-epar-product-information_bg.pdf)

español (ES) (729.46 KB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/es/documents/product-information/zilbrysq-epar-product-information_es.pdf)

čeština (CS) (814.18 KB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/cs/documents/product-information/zilbrysq-epar-product-information_cs.pdf)

dansk (DA) (728.02 KB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/da/documents/product-information/zilbrysq-epar-product-information_da.pdf)

Deutsch (DE) (1.04 MB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/de/documents/product-information/zilbrysq-epar-product-information_de.pdf)

eesti keel (ET) (761.61 KB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/et/documents/product-information/zilbrysq-epar-product-information_et.pdf)

ελληνικά (EL) (1.12 MB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/el/documents/product-information/zilbrysq-epar-product-information_el.pdf)

français (FR) (669.61 KB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/fr/documents/product-information/zilbrysq-epar-product-information_fr.pdf)

hrvatski (HR) (653.76 KB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/hr/documents/product-information/zilbrysq-epar-product-information_hr.pdf)

íslenska (IS) (706.84 KB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/is/documents/product-information/zilbrysq-epar-product-information_is.pdf)

italiano (IT) (1.23 MB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/it/documents/product-information/zilbrysq-epar-product-information_it.pdf)

latviešu valoda (LV) (817.46 KB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/lv/documents/product-information/zilbrysq-epar-product-information_lv.pdf)

lietuvių kalba (LT) (820.38 KB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/lt/documents/product-information/zilbrysq-epar-product-information_lt.pdf)

magyar (HU) (795.34 KB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/hu/documents/product-information/zilbrysq-epar-product-information_hu.pdf)

Malti (MT) (1.17 MB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/mt/documents/product-information/zilbrysq-epar-product-information_mt.pdf)

Nederlands (NL) (763.21 KB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/nl/documents/product-information/zilbrysq-epar-product-information_nl.pdf)

norsk (NO) (696.01 KB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/no/documents/product-information/zilbrysq-epar-product-information_no.pdf)

polski (PL) (1.08 MB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/pl/documents/product-information/zilbrysq-epar-product-information_pl.pdf)

português (PT) (767.4 KB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/pt/documents/product-information/zilbrysq-epar-product-information_pt.pdf)

română (RO) (794.1 KB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/ro/documents/product-information/zilbrysq-epar-product-information_ro.pdf)

slovenčina (SK) (1.01 MB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/sk/documents/product-information/zilbrysq-epar-product-information_sk.pdf)

slovenščina (SL) (656.41 KB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/sl/documents/product-information/zilbrysq-epar-product-information_sl.pdf)

Suomi (FI) (1.22 MB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/fi/documents/product-information/zilbrysq-epar-product-information_fi.pdf)

svenska (SV) (721.28 KB - PDF)

**First published:**

08/12/2023

**Last updated:**

26/11/2025

[View](/sv/documents/product-information/zilbrysq-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000310131 26/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zilbrysq : EPAR - All authorised presentations

English (EN) (44.83 KB - PDF)

**First published:** 08/12/2023

[View](/en/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-857)

български (BG) (53.14 KB - PDF)

**First published:**

08/12/2023

[View](/bg/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_bg.pdf)

español (ES) (16.83 KB - PDF)

**First published:**

08/12/2023

[View](/es/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_es.pdf)

čeština (CS) (56.22 KB - PDF)

**First published:**

08/12/2023

[View](/cs/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (17.57 KB - PDF)

**First published:**

08/12/2023

[View](/da/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (17.32 KB - PDF)

**First published:**

08/12/2023

[View](/de/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (16.2 KB - PDF)

**First published:**

08/12/2023

[View](/et/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (75.6 KB - PDF)

**First published:**

08/12/2023

[View](/el/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_el.pdf)

français (FR) (17.04 KB - PDF)

**First published:**

08/12/2023

[View](/fr/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (33.48 KB - PDF)

**First published:**

08/12/2023

[View](/hr/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (16.38 KB - PDF)

**First published:**

08/12/2023

[View](/is/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_is.pdf)

italiano (IT) (16.88 KB - PDF)

**First published:**

08/12/2023

[View](/it/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (56.77 KB - PDF)

**First published:**

08/12/2023

[View](/lv/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (56.89 KB - PDF)

**First published:**

08/12/2023

[View](/lt/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (58.04 KB - PDF)

**First published:**

08/12/2023

[View](/hu/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (67.22 KB - PDF)

**First published:**

08/12/2023

[View](/mt/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (17.16 KB - PDF)

**First published:**

08/12/2023

[View](/nl/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (42.08 KB - PDF)

**First published:**

08/12/2023

[View](/no/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_no.pdf)

polski (PL) (59.05 KB - PDF)

**First published:**

08/12/2023

[View](/pl/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_pl.pdf)

português (PT) (17.35 KB - PDF)

**First published:**

08/12/2023

[View](/pt/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_pt.pdf)

română (RO) (56.09 KB - PDF)

**First published:**

08/12/2023

[View](/ro/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (55.52 KB - PDF)

**First published:**

08/12/2023

[View](/sk/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (59.08 KB - PDF)

**First published:**

08/12/2023

[View](/sl/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (17.79 KB - PDF)

**First published:**

08/12/2023

[View](/fi/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (16.96 KB - PDF)

**First published:**

08/12/2023

[View](/sv/documents/all-authorised-presentations/zilbrysq-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Zilbrysq Active substance zilucoplan International non-proprietary name (INN) or common name zilucoplan Therapeutic area (MeSH) Myasthenia Gravis Anatomical therapeutic chemical (ATC) code L04AJ06

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Zilbrysq is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

## Authorisation details

EMA product number EMEA/H/C/005450

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

UCB Pharma S.A.

Allée de la Recherche 60

Opinion adopted 14/09/2023 Marketing authorisation issued 01/12/2023 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zilbrysq : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (143.99 KB - PDF)

**First published:** 29/04/2025

**Last updated:** 26/11/2025

[View](/en/documents/procedural-steps-after/zilbrysq-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Zilbrysq : EPAR - Procedural steps taken and scientific information after the authorisation (archive)

English (EN) (107.01 KB - PDF)

**First published:** 03/06/2024

**Last updated:** 29/04/2025

[View](/en/documents/procedural-steps-after/zilbrysq-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Zilbrysq : Orphan designation withdrawal assessment report

Adopted

Reference Number: EMA/OD/0000120845

English (EN) (693.62 KB - PDF)

**First published:** 13/12/2023

[View](/en/documents/orphan-maintenance-report/zilbrysq-orphan-designation-withdrawal-assessment-report_en.pdf)

Zilbrysq : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/439661/2023

English (EN) (2.41 MB - PDF)

**First published:** 08/12/2023

[View](/en/documents/assessment-report/zilbrysq-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Zilbrysq

Adopted

Reference Number: EMA/CHMP/404478/2023

English (EN) (103.84 KB - PDF)

**First published:** 15/09/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-zilbrysq_en.pdf)

#### News on Zilbrysq

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023) 15/09/2023

#### More information on Zilbrysq

This product is no longer an orphan medicine. It was originally designated an orphan medicine on 18 July 2022. Zylbrysq was withdrawn from the Union Register of orphan medicinal products by the European Commission in October 2023 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

**This page was last updated on** 26/11/2025

## Share this page

[Back to top](#main-content)